The effect of probiotics on fecal calprotectin in patients with cystic fibrosis

Turkish Journal of Pediatrics

Volumn 55, Issue 5, 2013, Pages 475-478

  Fallahi, Gholamhossein ^a   Motamed, Farzaneh ^a   Yousefi, Azizollah ^a   Shafieyoun, Arezoo ^a   Najafi, Mehri ^a   Khodadad, Ahmad ^a   Farhmand, Fatemeh ^a   Ahmadvand, Alireza ^b   Rezaei, Nima ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Calprotectin; Cystic fibrosis; Probiotics

Indexed keywords

CALGRANULIN; MALTODEXTRIN; PLACEBO; PROBIOTIC AGENT; PROTEXIN RESTOR; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; HUMAN; RANDOMIZED CONTROLLED TRIAL; CHEMISTRY; FECES;

CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FECES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; PROBIOTICS;

EID: 84890532573     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Werlin SL, Uri-Silbiger I, Kerem E, et al. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2010; 51: 304-308.
2. Smyth RL, Croft NM, O'Hea U, et al. Intestinal inflammation in cystic fibrosis. Arch Dis Child 2000; 82: 394-399.
3. Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005; 40: 450-455.
4. Fallahi G, Najafi M, Farhmand F. The clinical and laboratory manifestations of Iranian patients with cystic fibrosis. Turk J Pediatr 2010; 52: 132-138.
5. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 14-22.
6. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 32: 171-177.
7. Gray RD, Imrie M, Boyd AC, et al. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros 2010; 9: 193-198.
8. Bruzzese E, Raia V, Gaudiello G, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther 2004; 20: 813-819.
9. Lisowska A, Madry E, Pogorzelski A, et al. Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis. Scand J Clin Lab Invest 2010; 70: 322-326.
10. Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 2004; 72: 6040-6049.